KINAXIS
11.1.2024 13:01:50 CET | Business Wire | Press release
Kinaxis® Inc. (TSX: KXS), the leading supply chain management platform, today announced an expansion of its retail offering with the release of multiple new AI- and ML-powered innovations that provide retailers with end-to-end supply chain transparency, demand forecasting, and powerful simulation scenario planning capabilities to ensure customers can buy the goods they want, when and where they want them, regardless of unforeseen disruptions.
From unpredictable demand spikes driven by changing consumer habits and the rise of omni-channel commerce that seeks to provide a seamless shopping experience across multiple touchpoints, the retail landscape has never been more competitive, with retailers’ supply chains facing countless challenges that threaten their ability to keep customers happy and turn a profit.
Designed to simplify retailers’ ability to successfully manage the complexity of countless locations, SKUs, promotions and inventory variables that demand unparalleled decision-making, Kinaxis’ enhanced retail offering now includes:
- Demand.AI innovations – powerful machine-learning based models tailored to the scale and complexity of retailers that enables better understanding of how both internal (e.g. frequent price changes, new product introductions, changes to promotional plans) and external factors (e.g. social sentiment, weather, shifts in consumer behavior, local/national events) are influencing short and long-term demand for their products, and which can inform actions to maximize revenue opportunities and proactively resolve risks.
- Replenishment Planning – an all-new capability that enables retailers to better manage replenishment parameters across their supply chain to ensure every item at every store and distribution center gets restocked in a timely manner while establishing guardrails to protect stores from shipping excess inventory that would exceed their shelf-life capacity and increase their inventory holding costs.
- Demand Planning innovations – provides retailers with easy-to-interpret visualizations that explain demand patterns while enabling them to make instant adjustments to forecasts based on human insights around trends at any part of their supply chains, by product, geography, store, SKU, day and more.
“Faced with ever increasing consumer expectations, today’s retailers are in desperate need of solutions that enable them to make confident decisions around their supply chains at scale,” said Andrew Bell, chief product officer at Kinaxis. “With these latest innovations, businesses will finally be able to take the guesswork out of demand and replenishment planning with a view to creating a seamless and resilient end-to-end supply chain. And with additional investments on the horizon in promotion planning and allocation, we’re confident that retailers will continue to look to Kinaxis to help them provide their customers with the best products while ensuring their shelves are always fully stocked.”
The new retail-focused product innovations will enable Kinaxis to strengthen its position within the sector including with new customers like sporting goods leader Brooks Running and existing partners like HAVI, one of the world’s foremost experts in supply chain integration. Last year, Kinaxis and HAVI announced they were joining forces to innovate and transform the Quick Service Restaurant industry.
“With the pace of doing business speeding up and consumer behavior changing by the minute, companies can no longer rely on incremental improvements to their supply chain, which is why we were so thrilled to partner with Kinaxis who have proven their mettle for meeting the demanding needs of customers regardless of the industry,” said Rodney Brown, senior vice president and chief supply chain officer, North America and global planning and analytics at HAVI. “We’re eager to roll out these state-of-the-art capabilities to some of our largest customers and anticipate that they will immediately see the value they bring to their overall business.”
With more than 40,000 users in 100+ countries, Kinaxis works with some of the world’s biggest brands across all sectors including CPG, automotive, high tech, life sciences and more. Its AI-powered technology and patented concurrency technique allows companies to orchestrate their supply chain network end to end from strategic planning to last-mile delivery.
Kinaxis’ retail product innovations will be showcased at NRF 2024 from January 14 – 16, 2024, at the Jacob K. Javits Convention Center in New York City. Visit Kinaxis at Booth #4068.
About Kinaxis
Kinaxis is a global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111554461/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
